Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gynecologic 2Gastrointestinal 2Dermatologic 2Plasma cell 1Lymphoid 1Head & Neck 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Melanoma 2Esophageal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Pharyngeal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Specimen Handling 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × zimberelimab × Clear all
NCT04772989 2025-08-28

ARC-12

Arcus Biosciences, Inc.

Phase 1 Completed
94 enrolled
DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡